← SynDRA
ROLAPITANT
SynDRA canonical compound SYN0038480 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | TACR1 |
|---|
| Mechanism of action | neurokinin receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- TACR1 ANTAGONIST
- Neurokinin 1 receptor antagonist
- neurokinin receptor antagonist
Drug classes
- Neurokinin 1 Antagonists
- Neurokinin-1 Receptor Antagonists
- Neurotransmitter Agents
- Substance P/Neurokinin-1 Receptor Antagonist
- Cytochrome P450 2D6 Inhibitors
- P-Glycoprotein Inhibitors
- Breast Cancer Resistance Protein Inhibitors
ATC classes
- A04A · ANTIEMETICS AND ANTINAUSEANTS
Cross-references
Synonyms
- rolapitant hydrochloride
- varubi
- SCH619734
- SCH 619734
- Varuby
- SCH-619734
- Varubi
- UNII-NLE429IZUC
- NLE429IZUC
- (5S,8S)-8-(((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one
- (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one
- Rolapitant [USAN:INN]
- Varubi (TN)
- Rolapitant (USAN/INN)
- Rolapitant(sch619734)
- SCHEMBL354305
- GTPL5749
- CHEMBL3707331
- CHEBI:90908
- DTXSID90203740
- MolPort-035-942-975
- EX-A1288
- BCP09609
- ZINC3816514
- rolapitantum
- RefChem:57237
- A04AD14
- DTXCID20126231
- sch-619734
- Rolapitant free base
- MFCD23105917
- Rolapitant [INN]
- Rolapitant?
- Rolapitant (Standard)
- ROLAPITANT [MI]
- ROLAPITANT [USAN]
- ROLAPITANT [WHO-DD]
- orb1303855
Reported adverse events
- Dizziness
- Dyspepsia
- Hiccups
- Neutropenia
- Stomatitis
- Decreased appetite
- Urinary tract infection
Look up ROLAPITANT in the interactive SynDRA portal →